A phase II study of live-attenuated Listeria monocytogenes immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265)

被引：0
|
作者：
Huh, Warner King
Brady, William E.
Moore, Kathleen N.
Lankes, Heather A.
Monk, Bradley J.
Aghajanian, Carol
Dizon, Don S.
Fracasso, Paula M.
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] GOG Stat Data Ctr, Buffalo, NY USA
[3] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[4] New York State Dept Hlth, Roswell Pk Mem Inst, Gynecol Oncol Grp, Buffalo, NY 14263 USA
[5] Creighton Univ, Sch Med, St Josephs Hosp & Med Ctr, Phoenix, AZ USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[7] Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA
[8] Univ Virginia, Charlottesville, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3121
引用
收藏
页数：1
相关论文
共 19 条
  • [1] A phase 2 study of live-attenuated listens monocytogenes cancer immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265).
    Huh, Warner King
    Brady, William E.
    Moore, Kathleen N.
    Lankes, Heather A.
    Monk, Bradley J.
    Aghajanlan, Carol
    Dizon, Don S.
    Armstrong, Deborah K.
    Thaker, Premal H.
    Fracasso, Paula M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage I of the phase II GOG/NRG0265 study.
    Huh, Warner King
    Dizon, Don S.
    Powell, Matthew A.
    Leath, Charles A.
    Landrum, Lisa Michelle
    Tanner, Edward
    Higgins, Robert
    Ueda, Stefanie M.
    McHale, Michael T.
    Monk, Bradley J.
    Aghajanian, Carol
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
    Basu, Partha
    Mehta, Ajay
    Jain, Minish
    Gupta, Sudeep
    Nagarkar, Rajnish V.
    John, Subhashini
    Petit, Robert
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (04) : 764 - 772
  • [4] Phase II study of durvalumab alone or in combination with ADXS11-001 (AXAL) in recurrent/persistent or metastatic cervical cancer
    Slomovitz, B.
    Bradley, W. H.
    Ghamande, S.
    O'Malley, D. M.
    Huang, M.
    Chon, H. S.
    Vangala, S.
    Sheeri, S.
    Gutierrez, A. A.
    Moore, K. N.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 4 - 5
  • [5] Phase I study evaluating high-dose treatment with ADXS11-001, a Listeria monocytogenes-listeriolysin O (Lm-LLO) immunotherapy, in women with cervical cancer.
    Ghamande, Sharad A.
    Platt, Daniel
    Wheatley, Donna
    Rungruang, Bunja Jane
    Janik, John Edward
    Khleif, Samir
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Phase II study of ADXS11-001 in patients with persistent/recurrent, locoregional or metastatic squamous cell carcinoma of the anorectal canal.
    Fakih, Marwan
    O'Neil, Bert H.
    Chiorean, E. Gabriela
    Hochster, Howard S.
    Chan, Emily
    Mauro, David J.
    Eng, Cathy
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [7] Phase I study evaluating high dose ADXS11-001 treatment in women with carcinoma of the cervix.
    Ghamande, Sharad A.
    Dobbins, Robin
    Marshall, Lisa
    Wheatley, Donna
    Prince, Cheryl
    Mauro, David J.
    Janik, John Edward
    Khleif, Samir
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] P2 study of ADXS11-001 Immunotherapy in patients with persistent/recurrent, surgically unresectable locoregional, or metastatic squamous cell anal cancer
    Eng, C.
    Fakih, M.
    Amin, M.
    Morris, V.
    Hochster, H. S.
    Boland, P. M.
    Uronis, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a phase II study in Indian women with recurrent/refractory cervical cancer
    Basu, Partha
    Petit, Robert G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] FINAL RESULTS FROM A PHASE-II RANDOMIZED CONTROLLED STUDY EVALUATING ADXS11-001 IMMUNOTHERAPY TARGETING HPV-E7 IN WOMEN WITH RECURRENT/REFRACTORY CERVICAL CANCER
    Basu, Partha
    Petit, Robert
    Gupta, Sudeep
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 165 - 165
12